Preview

Epilepsy and paroxysmal conditions

Advanced search

Effectiveness, safety and assessing the results of drug therapy in patients with epilepsy

https://doi.org/10.17749/2077-8333/epi.par.con.2021.093

Full Text:

Abstract

On June 26, 2021, a meeting of the experts of the Russian League Against Epilepsy (RLAE) was held, dedicated to the effectiveness, safety and assessing the results of drug therapy in patients with epilepsy. Having considered the history of the issue and guided by domestic and foreign experience, the participants discussed the problems associated with the use of various antiepileptic drugs for different forms of epilepsy in patients of different sex and age. Special attention was paid to psychiatric comorbidity in patients with epilepsy, increasing their compliance with treatment and quality of life. The article presents the Resolution of RLAE experts meeting adopted as a result of the discussion.

About the Author

article Editorial

Russian Federation


References

1. Shorvon S.D. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909–1958. Epilepsia. 2009; 50 (Suppl. 3): 69–92. https://doi.org/10.1111/j.1528-1167.2009.02041.x.

2. Campos M.S., Ayres L.R., Morelo M.R., et al. Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses. Pharmacotherapy. 2016; 36 (12): 1255–71. https://doi.org/10.1002/phar.1855.

3. Campos M.S., Ayres L.R., Morelo M.R., et al. Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses. Int J Clin Pharm. 2018; 40 (3): 589–98. https://doi.org/10.1007/s11096-018-0641-9.

4. Strandberg M.C., Söderberg-Löfdal K., Kimland E., et al. Evidencebased anti-seizure monotherapy in newly diagnosed epilepsy: a new approach. Acta Neurol Scand. 2020; 142 (4): 323–32. https://doi.org/10.1111/ane.13312.

5. NICE. Epilepsies: diagnosis and management. Clinical guideline. URL: https://www.nice.org.uk/guidance/cg137 (дата обращения 15.07.2021).

6. Marson A., Burnside G., Appleton R., et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021; 397 (10282): 1375–86. https://doi.org/10.1016/S0140-6736(21)00246-4.

7. Kanner A.M. Psychiatric comorbidity in patients with developmental disorders and epilepsy: a practical approach to its diagnosis and treatment. Epilepsy Behav. 2002; 3 (6S1): 7–13. https://doi.org/10.1016/s1525-5050(02)00536-x.

8. Cramer J.A., Blum D., Reed M., et al. The influence of comorbid depression on seizure severity. Epilepsia. 2003; 44 (12): 1578–84. https://doi.org/10.1111/j.0013-9580.2003.28403.x.

9. Tellez-Zenteno J.F., Patten S.B., Jetté N., et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007; 48 (12): 2336–44. https://doi.org/10.1111/j.1528-1167.2007.01222.x.

10. Mosolov S.N., Kostyukova Е.G. Clinical guidelines for pharmacoprophylaxis of recurrent bipolar disorder. Part 2. Current Therapy of Mental Disorders. 2008; 3: 44–57 (in Russ.).

11. Mula M., Kanner A.M., Jetté N., Sander J.W. Psychiatric comorbidities in people with epilepsy. Neurol Clin Pract. 2021; 11 (2): e112–20. https://doi.org/10.1212/CPJ.0000000000000874.

12. Aaberg K.M., Bakken I.J., Lossius M.I., et al. Comorbidity and childhood epilepsy: a nationwide registry study. Pediatrics. 2016; 138 (3): e20160921. https://doi.org/10.1542/peds.2016-0921.

13. Josephson C.B., Lowerison M., Vallerand I., et al. Association of depression and treated depression with epilepsy and seizure outcomes: a multicohort analysis. JAMA Neurol. 2017; 74 (5): 533–9. https://doi.org/10.1001/jamaneurol.2016.5042.

14. Stephen L.J., Wishart A., Brodie M.J. Psychiatric side effects and antiepileptic drugs: observations from prospective audits. Epilepsy Behav. 2017; 71 (Pt. A): 73–8. https://doi.org/10.1016/j.yebeh.2017.04.003.

15. Frye R.E., Rossignol D., Casanova M.F., et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health. 2013; 1: 31. https://doi.org/10.3389/fpubh.2013.00031.

16. Moavero R., Santarone M.E., Galasso C., Curatolo P. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev. 2017; 39 (6): 464–9. https://doi.org/10.1016/j.braindev.2017.01.006.

17. Gusev Е.I., Burd G.S. Epilepsy: lamictal in the treatment of patients with epilepsy. Moscow: Buklet; 1994: 63 рр. (in Russ.).

18. Zenkov L.R. Lamictal in the treatment of epilepsy. Мoscow; 2006: 39 pp.

19. Karlov V.А. Epilepsy in children and adult women and men. A guide for doctors. 2nd ed. Мoscow: BINOM; 2020: 896 pp. (in Russ.).

20. Vlasov P.N., Dranko D.V., Agranovich О.V. Lamotrigine in the treatment of epilepsy in women. S.S. Korsakov Journal of Neurology and Psychiatry. 2011; 111 (5-2): 38–42 (in Russ.).

21. Resolution of the meeting of experts of the Russian League Against Epilepsy on the treatment of women with epilepsy. Epilepsia i paroksizmalʹnye sostoania / Epilepsy and Paroxysmal Conditions. 2019; 11 (2): 195–9 (in Russ.).


For citation:


Effectiveness, safety and assessing the results of drug therapy in patients with epilepsy. Epilepsy and paroxysmal conditions. 2021;13(3):306-310. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2021.093

Views: 146


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)